Data from the studies were presented at the 2019 European Association of Urology meeting in Barcelona, Spain.
The UroLift system uses tiny devices inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate, the Wayne, Penn.-based company said.
Teleflex said that it presented data from a real-world retrospective study of 30 men with
urinary retention treated with the UroLift system, with a goal of determining whether the UroLift would be an effective treatment as patients with urinary retention had been previously excluded.
“Our study confirmed that the UroLift System is an effective treatment in a very complex cohort, with 83% of men with urinary retention catheter-free in less than three days We also found significant improvement in prostatic symptom score, quality of life and post-void residuals, further demonstrating the effectiveness of the UroLift System treatment for men with BPH,” study author Dr. Thomas Mueller of New Jersey Urology said in a press release.
The company also highlighted that its device was featured in three other presentations at the conference, but did not release data from the presentations.
“Dr. Mueller’s real-world study and the other presentations shared at EAU are consistent with the value proposition of the UroLift System treatment for patients with BPH. These findings add to an extensive bank of clinical and real-world evidence affirming that the UroLift System is a safe and effective minimally invasive treatment that allows patients to achieve lasting relief from the burdensome symptoms of BPH,” Teleflex interventional urology biz prez Dave Amerson said in a press release.
Last month, Teleflex saw shares fall after the medical device maker released fourth quarter and full year 2018 earnings mostly in line with analysts expectations, as well as a 3-year, $56 million restructuring plan.